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Abstract
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and is important in moni-
toring the disease course and NET treatment.
Aim of the study: Usefulness of suppression test of CgA secretion with octreotide in diagnosis and predicting the therapy
outcome in NET patients.
Material and methods: The study included 32 patients with NET of gastrointestinal tract, lung and of unknown origin.
CgA level in blood plasma on fasting, before and 30, 60, 90 and 120 minutes after subcutaneous administration of 100 mg
octreotide, was determined in all patients. The subjects were divided into two subgroups with relation to CgA level and to
the results of somatostatin receptor scintigraphy (SRS).
Results: Statistically significant CgA decrease after octreotide administration in all study time points and positive results of
SRS were found in the patients with the elevated CgA level. No statistically significant decrease of CgA level after octreoti-
de was found in the group with normal CgA levels. In this group, 13 patients had a negative result of SRS, and somatostatin
receptors expression was found in one patient. Tolerance of somatostatin analogs (SSA) therapy was very good.
Conclusions: Octreotide suppression test with CgA level assessment in NET patients is a simple, straightforward examina-
tion, providing information on the predicted response to the applied SSA and the data on initial clinical tolerance of those
agents. This examination can also be a screening test useful in planning the treatment with SSA in patients with NET.
(Pol J Endocrinol 2007; 58 (2): 123129)
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Streszczenie
WstŒp: Chromogranina A (CgA) jest niespecyficznym markerem guzów neuroendokrynnych (NET). Jest ona przydatna
w monitorowaniu przebiegu choroby i leczenia chorych z NET.
Cel pracy: U¿ytecznoæ testu hamowania wydzielania CgA z u¿yciem oktreotydu w diagnostyce i prognozowaniu sku-
tecznoci terapii chorych z guzami neuroendokrynnymi.
Materia‡ i metody: Do badania w‡„czono 32 chorych z guzami neuroendokrynnymi uk‡adu pokarmowego, p‡uc i o nie-
znanym miejscu pochodzenia. U wszystkich badanych oznaczano stŒ¿enie CgA w osoczu krwi na czczo, przed oraz 30, 60,
90 i 120 minut po podaniu podskórnym 100 mg oktreotydu. Badane osoby podzielono na dwie podgrupy w zale¿noci od
stŒ¿enia CgA oraz wyniku scyntygrafii receptorów somatostatynowych.
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Wyniki: U chorych z podwy¿szonymi stŒ¿eniami CgA wykazano znamienne statystycznie obni¿enie stŒ¿enia CgA po
podskórnym podaniu oktreotydu w badanych punktach czasowych oraz dodatni wynik scyntygrafii receptorów somato-
statynowych (SRS). W grupie chorych z prawid‡owymi stŒ¿eniami CgA nie wykazano statystycznie znamiennego obni¿e-
nia stŒ¿enia CgA po podaniu oktreotydu. W tej grupie 13 chorych mia‡o ujemny wynik SRS, u jednego chorego stwierdzo-
no ekspresjŒ receptorów somatostatynowych. Tolerancja leczenia analogami somatostatyny (SSA) by‡a bardzo dobra.
Wnioski: Wykonywanie testu z oktreotydem z oznaczaniem stŒ¿eæ CgA u chorych z guzami neuroendokrynnymi jest
prostym, ‡atwym do wykonania badaniem daj„cym informacje o przewidywanej odpowiedzi na zastosowanie analogów
somatostatyny, jak równie¿ dostarczaj„cym danych na temat wstŒpnej tolerancji klinicznej tych preparatów. Badanie to
mo¿e byæ przesiewowym, przydatnym testem w planowaniu leczenia analogami somatostatyny u chorych z NET.
(Endokrynol Pol 2007; 58 (2): 123129)
S‡owa kluczowe: guzy neuroendokrynne, chromogranina A, test z oktreotydem
Introduction
Chromogranin A (CgA) is a non-specific marker of neu-
roendocrine tumors (NET). It is stored and secreted into
blood circulation together with other peptide hormo-
nes and biogenic amines from the neuroendocrine cells
through exocytosis and therefore it can be detected in
blood [1]. CgA is a stable molecule, its levels can be ele-
vated in most NETs, especially in classical carcinoid tu-
mors where CgA levels can be increased from 100 to
1000 times [2]. The elevated CgA levels, both in func-
tioning and non-functioning tumors, are connected
with the presence of metastases, mainly in the liver [1].
The increased CgA levels occur in 94% pancreatic tu-
mors, 99% malignant carcinoid tumor and gastroente-
ropancreatic neuroendocrine tumors (the highest levels
are found in metastasing midgut NETs) [3].
Treatment with somatostatin analogs (SSA) redu-
ces CgA, mainly in the patients with carcinoid tumors,
through suppression of CgA synthesis and secretion
from tumor cells. However, in the case of the disease
progressing at the time of SSA analog treatment, the
increased CgA level can reflect a lack of control of tu-
mor secretion function and/or its growth [2].
Octreotide was the first discovered synthetic soma-
tostatin analog. Its half-time is longer than the native
somatostatins one and it is (following the subcutane-
ous administration) 1.52.5 hours [4]. The biological in-
fluence of somatostatin and its analogs happens direc-
tly on somatostatin receptors (sstr) localized on the sur-
face of endocrine cells. There are 5 subtypes of the
known somatostatin receptors (sstr1-5). Octreotide has
the greatest affinity to somatostatin receptors type 2 and
smaller to types 5 and 3 [5, 6]. Many NETs have a great
number of receptors for somatostatin (80% of them
show the expression of type 2 receptor) and therefore
it can be imaged by radiolabelled SSA [7]. Long-term
somatostatin analogs can control the symptoms of hor-
monally active NETs which shows the expression of
somatostatin receptors [6, 8, 9].
There is still shortage of studies on the application
of somatostatin analogs suppression of CgA secretion
in diagnosis of patients with NET [2].
Aim of the study
The objective of the study was to carry out an octreotide
suppression test of CgA levels in patients with neuro-
endocrine tumors and to show the usefulness of the
test in connection with the result of somatostatin re-
ceptor scintigraphy and the clinical evaluation of me-
dication tolerance in including patients for somatosta-
tin analog treatment.
Material and methods
The study included 32 patients with neuroendocrine
tumors of gastrointestinal tract, lung and of unknown
origin hospitalized in the Division of Endocrinology in
Zabrze. The average age of the patients was 62 years
(– 38 years). The study group consisted of 14 women
(mean age 63 years) and 18 men (mean age 60 years).
During the course of the disease 24 patients underwent
surgery due to neuroendocrine tumors of gastrointe-
stinal tract, 9 of them had substitutive chemotherapy,
and 8 have not been treated since they were recently
admitted to the hospital.
Chromogranin A levels were determined before and
30, 60, 90 and 120 minutes after subcutaneous admini-
stration of 100 mg octreotide (Sandostatin, Novartis). The
study group was divided into two groups with rela-
tion to chromogranin A level in point 0 (group I inclu-
ded 18 patients with elevated CgA levels, group II con-
sisted of 14 patients with normal CgA levels) and the
result of SRS. The patients with other coexisting dise-
ases and conditions which could influence the chromo-
granin A levels, i.e. neoplastic diseases (of kidneys, pro-
state, breast, ovary, small cell lung carcinoma, thyroid
medullary carcinoma), pheochromocytoma, neurobla-
stoma, ACTH-dependent Cushings syndrome, liver,
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renal and cardiac insufficiency were excluded from the
study. The patients who had administered proton
pump inhibitors or H2-blockers had repeated exami-
nation after a ten-day break in the drug administration.
CgA was evaluated by the immunoenzymatic test
for chromogranin A quantitative marking in blood pla-
sma by EDTA (DakoCytomation, Denmark). Sensitivi-
ty and specificity of the set comes to 85% [10], referen-
ce values range 218 U/l. ELISA set for CgA marking is
a simplified immunoenzymatic sandwich test with two
antibodies, where samples and antichromogranin A
conjugated by peroxidase are incubated in microwells
coated with antichromogranin A.
All patients had somatostatin receptor scintigraphy
with use of 99mTc HYNIC-Tyr3-octreotate (Tektrotyd,
OBRI Polatom, Poland) done in the Department of
Nuclear Medicine and Endocrine Oncology of the On-
cology Institute in Gliwice.
The evaluation of clinical symptoms related to the
medication tolerance was performed in all the patients
24 hours after the octreotide test (questionnaire no 1).
Statistical analysis was carried out with the use of
Friedman test (p < 0.05 ) and Wilcoxon test.
Results
Table I and II present CgA levels in individual patients
with relation to type of GEP NET according to WHO
classification, a presence of metastases and somatosta-
tin receptor expression.
In the patients with the elevated CgA levels (group I)
a statistically significant decrease of CgA level after sub-
cutaneous octreotide administration in the time points
of the 30, 60, 90 and 120 minutes (Fig. 1, Table III)
and a positive result of somatostatin receptor scintigra-
phy were shown. Over 40% decrease of CgA level in
61% of the patients in the 90 minute test (Table IV) and
in 70% patients in the 120 minute test (Table V) was
found. In the group of patients with normal CgA le-
vels, no statistically significant decrease of CgA levels
after octreotide administration was shown. In this group,
13 patients had a negative result of somatostatin receptor
scintigraphy, in one patient a sstr expression was
found (Table II).
Table VI shows the evaluation of the presence of
clinical symptoms according to questionnaire no 1 in
all NET patients before and after octreotide administra-
tion. Dermal lesions at injection site, allergic reactions,
headaches, dizziness were not observed.
Discussion
Chromogranin A is a non-specific marker of neuro-
endocrine tumors which levels are considerably
elevated in groups of patients, especially with meta-
stases, what was confirmed in our study. The increased
CgA levels were shown in group I, in which most of the
neuroendocrine tumors were hormonally active, and
metastases were found in majority of the patients. One-
third of the group did not show hormonal activity,
which is consistent with data of other authors who claim
that non-functioning neuroendocrine tumors can often
cause elevated CgA levels in blood [11]. Group II
included patients with normal CgA levels, with non-
functioning tumors, after radical surgical treatment and
with pulmonary neuroendocrine tumors. Metastases
were found in this group only in 4 cases. Normal CgA
levels in this group (for example, patients with meta-
stases) could be a result, on the one hand, of sensitivity
and specificity of chromo-granin A marking and on the
other hand, of the lack of hormonal activity of those
tumors and the localization of primary focus in lungs.
Our observations confirm other authors opinions, i.e.
Peracchi et al. [11], in tests where sensitivity and specifi-
city of CgA marking was 2781% and it was related
to primary focus localization and degree of disease
advancement [11].
In our study the statistically significant decrease of
CgA was found in the group with elevated CgA levels
after octreotide subcutaneous administration at the
study time points, i.e. 30, 60, 90, and 120 minutes of the
test. 40% decrease of CgA level was shown in 61%
of patients at 90 minutes of the test and in 70% of
patients at 120 minutes of the test.
There are few reports in literature on the appli-
cation of octreotide suppression of CgA secretion in
diagnosis of patients with NET. In the study carried
out by Oberg et al. [2], who qualified patients with
hormonally active gastroenteropancreatic tumors
(GEP) for somatostatin analog treatment, 50% decrease
of CgA level at the time from 90 to 120 minutes since
subcutaneous 100 µg octreotide administration was
shown. The differences in our results could be a result
of a different sensitivity and specificity of the sets used
for CgA assessment and of a heterogeneous group of
patients taking part in the study (gastroenteropan-
creatic, lung and of unknown primary focus neuro-
endocrine tumors).
On the basis of those observations, a short-term
octreotide test with CgA level measurement before
the drug administration and at 90 and/or 120
minutes after its administration can be suggested
because here in most of the patients the CgA level
decreases by over 40%. This simple test can be useful
in the case of a decision about somatostatin analog
therapy while waiting for somatostatin receptor
scintigraphy since this examination is not commonly
available.
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Table II
NET patients with normal CgA levels (group II)
Tabela II
Chorzy z NET z prawid‡owymi stŒ¿eniami CgA (grupa II)
Patients WHO Tumor Hormonal Metastases CgA before CgA 30 CgA  60 CgA  90 CgA 120 SRS
initials type  origin activity  presence octreotide after after after after
[U/l] octreotide octreotide octreotide octreotide
[U/l] [U/l] [U/l] [U/l]
E.W. I Lung NF 12.04 9.55 12.04 11.08 8.87 ()
J.W. II Rectum NF L 10.54 13.41 10.96 10.13 9.72 (+)
Z.S. II Pancreas NF 13.08 13.08 11.74 7.50 7.36 ()
H.B. I Stomach NF 11.42 12.33 14.64 16.35 20.86 ()
J.K. II Unknown NF LN 18.63 18.44 12.39 10.96 25.93 ()
G.T. II Unknown NF L 22.18 24.76 23.12 22.55 16.99 ()
A.J. II Lung NF C,O 15.57 13.08 11.74 11.52 7.36 ()
A.C. I Rectum NF 14.67 13.20 11.50 10.00 9.75 ()
U.R. I Colon NF 10.60 9,80 8,30 7,50 7,00 ()
M.B. I Stomach NF 16.70 15,50 14,30 13.60 12.40 ()
S.B. I Small intestine NF 8.02 7.93 7.61 7.77 7.01 ()
H.K. I Lung NF 7.77 7.50 7.00 7.00 7.07 ()
G.W. I Pancreas NF 20.03 18.50 9.46 9.26 8.18 ()
D.Sz. I Small intestine NF 16.34 16.03 15.96 6.01 12.81 ()
NF  non-functioning tumor, L  metastases in liver, LN  metastases in lymph nodes, C  metastases in cerebellum, O  metastases in ovary,
SRS  somatostatin receptors scintigraphy
Table I
NET patients with the elevated CgA levels  (group I)
Tabela I
Chorzy z NET z podwy¿szonymi stŒ¿eniami CgA (grupa I)
Patients WHO Tumor Hormonal Metastases CgA before CgA 30 CgA 60 CgA 90 CgA 120 SRS
initials type  origin activity  presence  octreotide after after after after
[U/l]   octreotide octreotide octreotide octreotide
[U/l]    [U/l]    [U/l]    [U/l]
J.T. II Unknown NF L,T 1042.30 905.30 810.69 688.37 416.92 (+)
M.N. II Meckels F L 360.00 316.00 173.85 155.10 131.09 (+)
diverticulum
S.C. II Small intestine F L 384.06 238.42 199.53 150.41 120.01 (+)
Z.K. II Pancreas NF L 379.29 291.65 237.99 225.40 214.88 (+)
S.K. II Pancreas F LN 358.46 385.37 272.77 252.02 249.35 (+)
Z.H. II Unknown NF L 456.80 342.60 296.92 274.80 205.56 (+)
T.J. II Unknown F L 119.91 184.51 103.27 108.52 108.18 (+)
J.M. II Pancreas F L,B 810.40 664.76 625.92 576.80 545.60 (+)
L.D. II Small intestine F LN 700.00 689.99 466.42 382.72 347.24 (+)
K.P. II Small intestine F L 402.80 315.16 261.50 248.91 238.39 (+)
L.M. II Pancreas NF L 256.50 229.59 170.81 150.06 147.33 (+)
C.W. II Unknown F L, LN 534.60 446.96 393.30 380.71 370.18 (+)
K.M. II Small intestine F L 768.50 622.86 480.71 461.96 437.95 (+)
W.S. II Small intestine F L 302.74 215.10 161.44 148.85 138.33 (+)
L.F. II Stomach NF L 199.00 139.30 119.40 100.00 84.50 (+)
S.K. II Pancreas F LN 700.00 689.99 466.42 382.72 447.24 (+)
E.S. III Unknown NF P 269.23 205.44 78.56 98,78 114.36 (+)
H.Ch. I Stomach F No 51.63 46.87 38.41 37.58 31.18 (+)
NF  non-functioning tumor, F  functioning tumor, L  metastases in liver, T  metastases in thyroid, LN  metastases in lymph nodes,
B  metastases in bones, P  pulmonary metastases, SRS  somatostatin receptors scintigraphy, No  no metastases
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Figure 1. CgA levels before (0) and 30, 60, 90 and 120 minutes
after subcutaneous administration of 100 mg octreotide in patients
with NET in group I
Rycina 1. StŒ¿enia CgA przed (0) oraz 30, 60, 90 i 120 minut po
podskórnym podaniu 100 mg oktreotydu w grupie I chorych z NET
Table III
Mean decrease of CgA level after octreotide (100 mg)
administration at individual time points [%] in  group I with
NET
Tabela III
rednie obni¿enie stŒ¿enia CgA po podaniu oktreotydu (100 mg)
w poszczególnych punktach czasowych [%] w grupie I chorych
z NET
Time since octreotide 30 60 90 120
administration
Decrease of CgA level [%] 16% 32% 43% 45%
Table IV
Decrease of CgA level [%] in group I with NET at 90 minutes
after octreotide administration
Tabela IV
Obni¿enie stŒ¿enia CgA [%] w grupie I chorych z NET
w 90 minucie testu po podaniu oktreotydu
Decrease of CgA level < 40% 4060% > 60%
Number of patients 39% 50% 11%
61% patients with decreased CgA level > 40%
Table VI
Evaluation of clinical symptoms in all NET patients of the study groups before and after octreotide 100 mg s.c. administration
Tabela VI
Ocena objawów klinicznych w grupie badanych chorych przed i po podaniu oktreotydu 100 mg s.c.
Clinical Number (N) and (%) Number (N) of patients who after octreotide administration:
symptoms of patients presenting
clinical symptoms before decreased the symptoms increased developed new
octreotide administration symptoms  not changed  symptoms symptoms
Abdominal pain 7 (22%) 3 3 1 0
Diarrhea 6 (19%) 3 2 1 1
Flushing 6 (19%) 4 2 0 0
Nausea 1 (3%) 1 0 0 0
Vomiting 1 (3%) 1 0 0 0
Dyspepsia 4 (12.5%) 1 3 0 0
Dyspnea 5 (15.5%) 1 4 0  0
The study performed by Shi et al. [12] showed that
both a result of octreotide suppression test and
somatostatin receptor scintigraphy can be useful in
qualifying patients for treatment with long-term
somatostatin analogs.
The diagnosing and evaluation of neuroendocrine
tumors advancement includes CgA level assessment in
blood (NET biochemical tumor marker) and SRS. In our
study, we showed the expression of somatostatin
receptors in all patients with elevated CgA levels, which
is consistent with the observations of Kalkner et al. [13]
*p < 0.05 vs. CgA before octreotide administration
Table V
Decrease of CgA level [%] in group I with NET at 120 minutes
after octreotide administration
Tabela V
Obni¿enie stŒ¿enia CgA [%] w grupie I chorych z NET
w 120. minucie testu po podaniu oktreotydu
Decrease of CgA level < 40% 4060% > 60%
Number of patients 30% 45% 25%
       70% patients with decreased CgA level  > 40%
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who showed that there is a correlation between
a positive result of somatostatin receptor scintigraphy
and the elevated CgA level in blood, although SRS
seems to be more sensitive than CgA, it is as specific as
CgA [13, 14].
In the group with normal CgA levels, 13 patients
had a negative result of somatostatin receptor
scintigraphy. Somatostatin receptor expression was
found in one patient with the NET of the hindgut type
with metastases in the liver. Our results are consistent
with the observations of Cimitan et al. [14] who proved
that specificity of somatostatin receptor scintigraphy
and CgA assessment for neuroendocrine tumors comes
to 94%. They [14] also observed false positive results of
scintigraphy in the case of a patient with a limited
disease, while false positive CgA marking was found
in a patient with well differentiated neuroendocrine
carcinoma with accompanying arterial hypertension
and arrhythmia. In our study, somatostatin receptor
scintigraphy was done with the use of 99mTc HYNIC-
Tyr3-octreotate (tectrotide), where as most studies
described in literature applied 111 In-pentetreotide,
which is where the diversity in results can come from.
Our study proved a good tolerance to short-term
somatostatin analogs. In the study groups, 24 hours after
subcutaneous short-term octreotide administration,
an alleviation of paroxysmal flushing was noted in
4 patients, decreased number of stools per day in
3 patients, and an increase of abdominal pain and
diarrhea only in one patient. According to the published
data, somatostatin analogs are safe drugs, easy to use
and well tolerated by patients [9]. Meteorism, diarrhea
or abdominal pain occur in less than 10% of patients
under the treatment [15, 16].
Summarizing the results of our observation, it can
be stated that octreotide test with CgA level assessment
in patients harboring  neuroendocrine tumors is
a simple, straightforward examination providing
information on a possible response to somatostatin
analogs and also supplying details on initial clinical
tolerance of those agents. This examination can also be
an useful screening test in planning the somatostatin
analog therapy in patients with NET.
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